Expanding its life sciences patent litigation group in New York, McGuireWoods has hired a trio of partners from Baker & Hostetler who specialize in guiding companies through disputes related to intellectual property protections on branded and generic drugs.

The three lateral hires, Benjamin Hsing, Wanda French-Brown and Irene Hudson, have worked alongside each other for about three years and started at McGuireWoods on Wednesday, they said in an interview. As a group, they have experience handling litigation stemming from abbreviated new drug applications (ANDAs)—the process set out under the Hatch-Waxman Act that regulates when and how generic drugs can come to market.

Benjamin Hsing, McGuireWoods